Quarterly ResultMay 6, 2026, 04:58 PM
Zomedica Q1 Revenue $8.8M, +35% YoY; Record 21st Straight Quarter
AI Summary
Zomedica Corp. announced record first-quarter revenue of $8.8 million for Q1 2026, reflecting 35% annual growth and marking the 21st consecutive quarter of year-over-year revenue increase. Performance was driven by strong sales of therapeutic devices, continued adoption of diagnostic offerings like TRUFORMA®, and contributions from the newly formed Development Services segment, which generated $2.0 million. The company also reported a 21% reduction in adjusted operating expenses and a 15% decrease in cash burn, while maintaining $47.5 million in liquidity.
Key Highlights
- Revenue for Q1 2026 grew 35% to $8.8 million, marking the 21st consecutive quarter of year-over-year growth.
- Diagnostics segment revenue increased 73% year-over-year to $1.0 million.
- Development Services segment generated $2.0 million in revenue for the quarter.
- Consumable revenues grew 22% from Q1 2025 to $5.5 million.
- Adjusted operating expenses decreased 21% to $10.4 million compared to Q1 2025.
- Cash burn for the quarter was down 15% to $5.7 million.
- Net loss for Q1 2026 was $4.5 million, significantly reduced from $63.8 million in Q1 2025.
- The company maintained $47.5 million in cash, cash equivalents, and available-for-sale securities.
Price Impact
More from ZOMDF